Technical Analysis for ICPT - Intercept Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
B 17.0 -2.58% -0.45
ICPT closed down 2.58 percent on Thursday, January 20, 2022, on 78 percent of normal volume. The stock fell below its 200 day moving average, damaging its long-term outlook by crossing under that critical trendline.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Up Up
Historical ICPT trend table...

Date Alert Name Type % Chg
Fell Below 200 DMA Bearish 0.00%
Crossed Above 200 DMA Bullish -2.58%
Crossed Above 20 DMA Bullish -2.58%
Crossed Above 50 DMA Bullish -2.58%
Fell Below 200 DMA Bearish 2.66%
Fell Below 20 DMA Bearish 2.66%
Fell Below 50 DMA Bearish 2.66%
Inside Day Range Contraction 2.66%
Crossed Above 200 DMA Bullish -4.28%
Crossed Above 20 DMA Bullish -4.28%
Older End-of-Day Signals for ICPT ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Down 2 % about 11 hours ago
Down 1% about 12 hours ago
60 Minute Opening Range Breakdown about 12 hours ago
Fell Below 200 DMA about 12 hours ago
Possible NR7 about 12 hours ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Intercept Pharmaceuticals, Inc. Description

Intercept Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat chronic liver diseases utilizing proprietary bile acid chemistry. It primarily develops obeticholic acid, a bile acid analog and farnesoid X receptor (FXR) agonist that is in Phase III clinical trials for the treatment of primary biliary cirrhosis; in Phase IIa clinical trials to treat portal hypertension; in Phase IIb clinical trials for the nonalcoholic steatohepatitis treatment; and in Phase IIa trials for the treatment of bile acid diarrhea. The company is also developing INT-767, an orally administered FXR and TGR5 agonist, which is in preclinical studies to treat fibrosis; and INT-777, an orally administered TGR5 agonist that has completed preclinical studies for the treatment of type 2 diabetes. It has strategic collaborations and research agreements with Dainippon Sumitomo Pharma Co. Ltd. and TES Pharma Srl. The company was founded in 2002 and is headquartered in New York, New York. Intercept Pharmaceuticals, Inc. is a subsidiary of Genextra S.p.A.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Acid Alcohol Diabetes Hypertension Gastroenterology Steatohepatitis Diarrhea Hepatology Liver Disease Fibrosis Digestive Diseases Bile Acid Chronic Liver Disease Chronic Liver Diseases Primary Biliary Cholangitis Cirrhosis Farnesoid X Receptor Fxr Obeticholic Acid

Is ICPT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 38.94
52 Week Low 11.6
Average Volume 799,795
200-Day Moving Average 17.35
50-Day Moving Average 16.75
20-Day Moving Average 16.64
10-Day Moving Average 16.44
Average True Range 1.21
ADX 18.29
+DI 23.01
-DI 12.13
Chandelier Exit (Long, 3 ATRs) 14.66
Chandelier Exit (Short, 3 ATRs) 18.07
Upper Bollinger Bands 18.31
Lower Bollinger Band 14.97
Percent B (%b) 0.61
BandWidth 20.09
MACD Line 0.12
MACD Signal Line -0.02
MACD Histogram 0.1362
Fundamentals Value
Market Cap 560.87 Million
Num Shares 33 Million
EPS -10.44
Price-to-Earnings (P/E) Ratio -1.63
Price-to-Sales 3.90
Price-to-Book 44.19
PEG Ratio -0.69
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.84
Resistance 3 (R3) 19.02 18.60 18.53
Resistance 2 (R2) 18.60 18.13 18.50 18.43
Resistance 1 (R1) 17.80 17.84 17.59 17.61 18.33
Pivot Point 17.37 17.37 17.27 17.28 17.37
Support 1 (S1) 16.57 16.90 16.36 16.39 15.67
Support 2 (S2) 16.15 16.61 16.05 15.57
Support 3 (S3) 15.35 16.15 15.47
Support 4 (S4) 15.16